Globus Medical stock: context for recent moves

Globus Medical (GMED) has been on many investors’ radars after recent trading, with the stock down about 14% over the past month and roughly 13% over the past 3 months despite solid profitability metrics.

While the share price has retreated recently, with the latest close at US$77.95 and short term momentum fading, the 1 year total shareholder return of 30.66% and 3 year total shareholder return of 39.00% still point to a very different experience for longer term holders.

If you are comparing Globus Medical with other growth stories in medical technology and robotics, it may be worth scanning a broader universe of healthcare focused AI and automation plays via 39 healthcare AI stocks

With GMED trading at US$77.95, alongside annual revenue of about US$3.1b and net income of roughly US$586.7m, the key question is whether the current valuation leaves upside on the table or if the market already reflects its future growth prospects.

Most Popular Narrative: 30.1% Undervalued

Against the last close of $77.95, the most followed narrative points to a fair value of $111.50, framing Globus Medical as materially undervalued and rooted in a detailed view of growth, margins and capital allocation.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and robust product pipeline position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Want to see what sits behind that fair value jump? The narrative leans heavily on steady top line expansion, firm margins and a richer earnings multiple. Curious which assumptions really move the model and how they add up to that target price?

Result: Fair Value of $111.50 (UNDERVALUED)

However, this hinges on smoother integration of NuVasive and Nevro, and on US Core Spine growth meeting expectations, with prolonged sales cycles a clear swing factor.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of recent weakness and longer term strength feels mixed, treat it as a prompt to review the data yourself and move early to shape your own view. To see what investors are currently optimistic about, start with the 5 key rewards

Looking for more investment ideas?

Do not stop at a single stock. Widen your search with data driven stock lists so you can quickly compare quality, value and resilience across the market.

• Target potential upside by scanning 47 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their profiles.
• Prioritize staying power by reviewing solid balance sheet and fundamentals stocks screener (47 results) that keep financial strength front and center.
• Get ahead of the crowd by checking a screener containing 22 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.